Literature DB >> 12587618

Limited value of routine microbiological diagnostics in patients hospitalized for community-acquired pneumonia.

Christer Lidman1, Lars G Burman, Asa Lagergren, Ake Ortqvist.   

Abstract

Current guidelines recommend microbiological diagnostic procedures as a part of the management of patients hospitalized for community-acquired pneumonia (CAP), but the value of such efforts has been questioned. Patients hospitalized for CAP were studied retrospectively, focusing on the use of aetiological diagnostic methods and their clinical impact. Adult patients, without known human immunodeficiency virus infection, admitted to hospital for CAP during 12 months, were evaluated with regard to the importance of aetiological diagnosis for tailoring antibiotic therapy, antibiotic-associated diarrhoea, Clostridium difficile disease, length of hospital stay and mortality. Of the 605 studied patients, 482 (80%) were subjected to Mycoplasma pneumoniae and/or respiratory virus serology and/or cultures of blood and/or sputum. They had a better prognosis than patients not subjected to microbiological diagnostics (mortality within 3 months was 9% vs 24%, p = 0.001), apparently reflecting differences in general health (e.g. less dementia diagnosis) but not the outcome of diagnostics. A presumptive aetiology was obtained only in 132 of the 482 patients, Streptococcus pneumoniae and M. pneumoniae being the most common agents (in 49 and 36 patients, respectively). Establishing an aetiological diagnosis had no impact on the number of in-hospital changes of therapy, on the proportion of new regimens having a narrower antimicrobial spectrum than the initial one or on the outcome. Therapy was changed to a drug directed specifically against the identified pathogen in only 16 out of these 132 patients and again without any overall improvement in the outcome variables. In a setting with a low frequency of antibiotic-resistant respiratory tract pathogens current routine microbiological diagnostics were found to be of limited value for the clinical management of patients hospitalized for CAP. Improved diagnostics in CAP are urgently needed, as establishing an aetiological diagnosis carries a potential for optimizing the antibiotic therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12587618     DOI: 10.1080/0036554021000026967

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  11 in total

Review 1.  [Contribution of microbiological investigations to the diagnosis of lower respiratory tract infections].

Authors:  O Leroy
Journal:  Med Mal Infect       Date:  2006-11-13       Impact factor: 2.152

2.  Routine surveillance for bloodstream infections in a pediatric hematopoietic stem cell transplant cohort: Do patients benefit?

Authors:  Heather Rigby; Conrad V Fernandez; Joanne Langley; Tim Mailman; Bruce Crooks; Ann Higgins
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-07       Impact factor: 2.471

3.  Evaluation of yield of currently available diagnostics by sample type to optimize detection of respiratory pathogens in patients with a community-acquired pneumonia.

Authors:  Elisabeth G W Huijskens; John W A Rossen; Jan A J W Kluytmans; Adri G M van der Zanden; Marion Koopmans
Journal:  Influenza Other Respir Viruses       Date:  2013-08-20       Impact factor: 4.380

Review 4.  Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association.

Authors:  Bin Cao; Yi Huang; Dan-Yang She; Qi-Jian Cheng; Hong Fan; Xin-Lun Tian; Jin-Fu Xu; Jing Zhang; Yu Chen; Ning Shen; Hui Wang; Mei Jiang; Xiang-Yan Zhang; Yi Shi; Bei He; Li-Xian He; You-Ning Liu; Jie-Ming Qu
Journal:  Clin Respir J       Date:  2017-09-26       Impact factor: 2.570

5.  Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.

Authors:  Joshua P Metlay; Grant W Waterer; Ann C Long; Antonio Anzueto; Jan Brozek; Kristina Crothers; Laura A Cooley; Nathan C Dean; Michael J Fine; Scott A Flanders; Marie R Griffin; Mark L Metersky; Daniel M Musher; Marcos I Restrepo; Cynthia G Whitney
Journal:  Am J Respir Crit Care Med       Date:  2019-10-01       Impact factor: 21.405

6.  Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction.

Authors:  Kate E Templeton; Sitha A Scheltinga; Willian C J F M van den Eeden; A Willy Graffelman; Peterhans J van den Broek; Eric C J Claas
Journal:  Clin Infect Dis       Date:  2005-06-22       Impact factor: 9.079

7.  Assessment of a new algorithm in the management of acute respiratory tract infections in children.

Authors:  Seyed Ahmad Tabatabaei; Seyed Alireza Fahimzad; Ahmad Reza Shamshiri; Farideh Shiva; Shadab Salehpor; Shirin Sayyahfar; Ghamartag Khanbabaei; Shahnaz Armin; Sedigheh Rafil Tabatabaei; Alireza Khatami; Maryam Kadivar
Journal:  J Res Med Sci       Date:  2012-02       Impact factor: 1.852

8.  Provider Decisions to Treat Respiratory Illnesses with Antibiotics: Insights from a Randomized Controlled Trial.

Authors:  Angela R Branche; Edward E Walsh; Nagesh Jadhav; Rachel Karmally; Andrea Baran; Derick R Peterson; Ann R Falsey
Journal:  PLoS One       Date:  2016-04-04       Impact factor: 3.240

9.  Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study.

Authors:  Daniel M Musher; Ingrid L Roig; Guillermo Cazares; Charles E Stager; Nancy Logan; Hossam Safar
Journal:  J Infect       Date:  2013-03-19       Impact factor: 6.072

10.  Treatment of Community-Acquired Pneumonia During the Coronavirus Disease 2019 (COVID-19) Pandemic.

Authors:  Joshua P Metlay; Grant W Waterer
Journal:  Ann Intern Med       Date:  2020-05-07       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.